BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of over 1000 found
  Current Search:  new: 87722, drug: 50564, class: 7158     

HTML
100%
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Ac
- Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons or entities who purchased the...
Pharma Live:  Mar 20 2010 1:22PM
Matching: new drug class
Find similar documents
HTML
100%
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Ac
Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons or entities who purchased the...
Genetic Engineering News:  Mar 20 2010 11:57AM
Matching: new drug class
Find similar documents
HTML
100%
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Action Lawsuit and Seeks to Recover Losses
LOS ANGELES-- (BUSINESS WIRE) -- Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons...
SmartBrief:  Mar 20 2010 1:35AM
Matching: new drug class
Find similar documents
HTML
100%
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Ac
Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Western District of Washington on behalf of a class consisting of all persons or entities who purchased the...
Genetic Engineering News:  Mar 20 2010 1:21AM
Matching: new drug class
Find similar documents
HTML
100%
FDA: High-Dose Simvastatin Given With Certain Drugs Increases Risk of Myopathy
my personal edition> cholesterol/lipid disorders > news E-Mail this DGNews to a colleague DGNews ROCKVILLE, Md -- March 19, 2010 -- Based on review of data from a large clinical trial and data from other sources, the US Food and Drug...
Doctors Guide:  Mar 20 2010 6:14AM
Matching: new drug class
Find similar documents
HTML
100%
Jury finds Seroquel didn't cause diabetes
TRENTON - AstraZeneca P.L.C.'s blockbuster psychiatric drug Seroquel did not trigger diabetes in a Vietnam veteran, a jury found yesterday in the first trial out of thousands of cases alleging the powerful drug caused diabetes.

The British...

Philly.com:  Mar 20 2010 5:06AM
Matching: new drug class
Find similar documents
HTML
100%
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Cell Therapeutics, Inc., Announces Class Ac
A copy of the Complaint is available from the court or from Glancy Binkow & Goldberg LLP.

Please contact us by phone to discuss this action or to obtain a copy of the Complaint at (310) 201-9150 or Toll Free at (888) 773-9224, by email at shareholders...

Therapeutics Daily:  Mar 20 2010 12:18PM
Matching: new drug class
Find similar documents
HTML
100%
Scientists Honored With Discoverers Award for Development of Innovative HIV Medicine Maraviroc
10:46 AM EDT WASHINGTON, March 18 /PRNewswire-USNewswire/ -- Three scientists who led the 11-year quest to develop a groundbreaking HIV drug today received the 2010 Discoverers Award -- the highest honor given to scientists by the Pharmaceutical Research...
National AIDS Treatment Advocacy Project:  Mar 20 2010 11:09PM
Matching: new drug class
Find similar documents
HTML
100%
::: Synergy Pharmaceuticals Initiates Phase IIa Clinical Trial of SP-304 in Patients with Chronic Constipation
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc.

(OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients...

Biotech Intelligence:  Mar 20 2010 9:02PM
Matching: new drug class
Find similar documents
HTML
100%
Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study
Drugs to treat cardiovascular conditions top the list in both use and cost for public drug programs Almost two-thirds (62%) of Canadians age 65 and older living in the community in six provinces are using five or more classes of prescription ...
News-Medical.Net:  Mar 19 2010 8:18AM
Matching: new drug class
Find similar documents
HTML
100%
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
Author : Dow Jones & Company Category : Press Release News Alerts by Email ( click here ) News | Home NEW YORK, March 19 -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of...
Earthtimes.org:  Mar 19 2010 2:30PM
Matching: new drug class
Find similar documents
HTML
100%
UPDATE: FDA panel green-lights BSX on expanded CRT-D indication
Boston Scientific Corp.

wins an important decision before a Food & Drug Administration panel, which granted its application to extend the indication for its implantable defibrillators to cover milder forms of heart failure.

If the FDA clears the...

MassDevice:  Mar 19 2010 10:43PM
Matching: new drug class
Find similar documents
HTML
100%
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
FinanzNachrichten.de:  Mar 19 2010 2:27PM
Matching: new drug class
Find similar documents
HTML
100%
The Drugs Are Working For Roche
Roches investor day left little doubt about the Swiss pharmaceutical giants conviction that its experimental drug pipeline will keep it on the path of success.

The firm touted that about ten experimental medicines could reach annual sales of more than 2...

Wall Street Journal Online:  Mar 19 2010 12:26PM
Matching: new drug class
Find similar documents
HTML
100%
Somaxon Stock Wakes Up On FDA Approval Of Sleep Drug - Update
(RTTNews) - Persistence has paid off for development-stage biotech company Somaxon Pharmaceuticals Inc.

(SOMX).

The company's insomnia drug candidate Silenor, which has been thrice at the FDA altar, finally won the regulatory approval Thursday,...

Canada News Wire via Quote.com:  Mar 19 2010 9:41AM
Matching: new drug class
Find similar documents
HTML
100%
Somaxon Stock Wakes Up On FDA Approval Of Sleep Drug - Update
(RTTNews) - Persistence has paid off for development-stage biotech company Somaxon Pharmaceuticals Inc.

(SOMX).

The company's insomnia drug candidate Silenor, which has been thrice at the FDA altar, finally won the regulatory approval Thursday,...

Quote.com United States:  Mar 19 2010 9:18AM
Matching: new drug class
Find similar documents
HTML
100%
FDA green-lights BSX on expanded CRT-D indication
Boston Scientific Corp.

wins an important decision before a Food & Drug Administration panel, which granted its application to extend the indication for its implantable defibrillators to cover milder forms of heart failure.

A Food & ...

MassDevice:  Mar 19 2010 8:57AM
Matching: new drug class
Find similar documents
HTML
100%
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
See more news releases in: Publishing & Information Services, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Surveys, Polls and Research NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company...
PR Newswire:  Mar 19 2010 2:26PM
Matching: new drug class
Find similar documents
HTML
100%
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
Columbus Business First:  Mar 19 2010 5:11PM
Matching: new drug class
Find similar documents
HTML
100%
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
Pittsburgh Business Times:  Mar 19 2010 4:32PM
Matching: new drug class
Find similar documents
HTML
100%
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
Wichita Business Journal:  Mar 19 2010 4:29PM
Matching: new drug class
Find similar documents
HTML
100%
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
Orlando Business Journal:  Mar 19 2010 3:28PM
Matching: new drug class
Find similar documents
HTML
100%
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
Companies mentioned in this article: Dow Jones & Company NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires...
Freshnews.com:  Mar 19 2010 3:16PM
Matching: new drug class
Find similar documents
HTML
100%
Dow Jones First to Report on Labopharm's Drug Side Effects; Subscribers Get Ahead of Markets As News Sends Company's Stock Down 5%
NEW YORK, March 19 /PRNewswire/ -- After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to...
Dow Jones:  Mar 19 2010 2:39PM
Matching: new drug class
Find similar documents
HTML
100%
Three scientists receive 2010 Discoverers Award for developing new class of HIV drug
Three scientists who led the 11-year quest to develop a groundbreaking HIV drug today received the 2010 Discoverers Award -- the highest honor given to scientists by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The honorees are Tony...

News-Medical.Net:  Mar 19 2010 4:55AM
Matching: new drug class
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.